AmpliPhi Biosciences Corp plans to issue shares of its common stock in a public offering.

The US-based clinical-stage biotechnology company plans to use proceeds for general corporate expenses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

US-based immuno-oncology company Argos Therapeutics Inc plans to raise $1.5m through the private placement of 7.5 million shares of its common stock priced at $0.20 a share.

Lummy Hong Kong Co Ltd has subscribed to the private placement.

Juvenescence Limited has raised $12.3m in seed financing from angel investors and institutions that include Foresite Capital, Karim Hakimzadeh, Andrew Banks and Christian Angermayer’s Apeiron Investment Group.

In addition, founders of the company chairman Jim Mellon and chief executive officer Gregory Bailey each provided $1.5m.

Juvenescence is a UK-based company involved in the development of therapeutics for ageing and age-causing diseases. The company plans to use the funds to form collaborations with academic institutions.

“The latest transaction has increased the total amount raised to $21.63m.”

Alder Biopharmaceuticals Inc plans to raise $250m through the private placement of shares of its class A preferred stock.

The placement will be subscribed to by affiliated institutional and accredited investors.

The biopharmaceutical company plans to use the funds towards the payment of European patent settlement and signing a global licence agreement with Teva Pharmaceuticals International GmbH, as well as for working capital and general corporate purposes.

Storm Therapeutics Ltd (formerly Iceni Therapeutics) has secured £4m ($5.42m) in a series A financing round led by Taiho Ventures LLC, the venture capital division of Taiho Pharmaceutical Co Ltd.

Storm previously raised £12m ($15.96m) in June 2016 from existing investors, Imperial Innovations Group Plc, Cambridge Innovation Capital Plc, Merck Ventures BV and Pfizer Venture Investments.

The latest transaction has increased the total amount raised to £16m ($21.63m).

The US-based cancer drug development company plans to use funds to expand its pipeline and broaden its drug discovery platform.